---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-26-000030"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2026-06-08T10:11:32+00:00"
generated_at: "2026-06-08T10:15:27.022363+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Nurix receives $700M upfront from Roche to co-develop BTK degrader bexobrutideg; potential $2.3B total

## Summary
- Upfront cash payment of $700 million; potential development, regulatory and sales milestones up to $2.3 billion total.
- Development costs shared 40% Nurix / 60% Roche; U.S. profits and losses split equally.
- Ex-U.S. royalties range from low-teens to high-teens on net sales; Roche leads commercialization outside U.S.
- Expansion into immunology and neurology: Phase 2 trials planned in multiple sclerosis and chronic spontaneous urticaria.
- Co-development and co-commercialization in U.S. across malignant hematology; Nurix becomes fully integrated biotech.

## SEC filing metadata
- accession: 0001549595-26-000030
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2026-06-08T10:11:32+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000030/0001549595-26-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000030/nrix-20260606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-26-000030
- JSON: https://secwatch.observer/filing/0001549595-26-000030.json
- Plain text: https://secwatch.observer/filing/0001549595-26-000030.txt

## Key facts
- Material Agreements
  Nurix Therapeutics, Inc. entered into Collaboration Agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. valued at $700.0 million (effective 2026-06-06).
  - Action: entry
  - Agreement: license
  - Counterparty: F. Hoffmann-La Roche Ltd. and Genentech, Inc.
  - Value: $700.0 million
  - Effective: 2026-06-06
  source text: On June 6, 2026, Nurix Therapeutics, Inc. (" Nurix ") entered into a License and Collaboration Agreement (the " Collaboration Agreement "), dated as of June 8, 2026, with F. Hoffmann-La Roche Ltd. and Genentech, Inc. (collectively, " Roche ")
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000030/0001549595-26-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.